Targos - A Leader in Biomarker Services for more than 10 years

Targos core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry.

The company has supported more than 400 international clinical trials since 2005, which have led to the successful approval of several targeted therapies and IVDs for our customers.

The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the market.

Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). Since 2014 Targos Molecular Pathology GmbH is accredited by the College of American Pathologists and the US-CLIA program.

Targos News

We celebrate with our partner, Roche, on the success of the Phase III KATHERINE study!

Press Information

Basel, 15 October 2018

We’d like to congratulate our partner Roche, on the success of their recent Phase III study investigating a new treatment option for people with HER2-positive early breast cancer with residual disease following neoadjuvant treatment. Targos is proud to have played a role in supporting the pre-screening of patients enrolled in the trial – by enabling confirmation of informative tumour characteristics such as HER2 status. We celebrate this important advance, which brings new hope to patients with this aggressive disease.